Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2006

View Archived Issues

BT-11: procognitive dietary supplement for SMI or MCI

F-15599: new 5-HT1A targeting antidepressant candidate

Preclinical characterization and pharmacokinetics of the novel DPP-IV inhibitor GRC-8011

Preclinical and clinical antidiabetic and antiobesity efficacy of the GLP-1 analogue liraglutide

Baraclude launched in Japan

Japanese launch for Cetrotide for use in IVF

Pivotal results for icatibant in hereditary angioedema

Itax development discontinued in functional dyspepsia and diabetic gastropathy

Tarceva studied as adjuvant treatment in NSCLC

Inex shareholders approve spin-out of Tekmira

European orphan drug designation for Debio-0513 in myasthenia gravis

AT-1001 studied in phase II trial for celiac disease

Development of TZP-101 extended to include patients with gastroparesis

Dimebon meets all five efficacy endpoints in Alzheimer's study

EVT-201 studied in phase II insomnia trial

German clearance for phase IIb/III study of BF-200 ALA

Inhaled powder formulation of Ostabolin-C studied in phase I trial

Novel antiinfective agents disclosed in recent patent literature

Novel oncolytic drugs revealed in recent patents

Novel 5-HT4 receptor agonists for gastrointestinal disorders emerge from Pfizer R&D

R&D highlights from the UBS Global Life Sciences Conference in New York: Cipher Pharmaceuticals

Approvable letter for Factive in five-day treatment of CAP

Gardasil approved in E.U.

Fentora approved for management of cancer breakthrough pain

Taxotere recommended for approval in Europe for head and neck cancer

Lamictal approved for new epilepsy indication

Merck & Co. reports on new bradykinin B1 receptor antagonists

New apoptosis inducers developed at Advanced Life Sciences

3M Pharmaceuticals reveals new TLR7 receptor agonist

Improved oral bioavailability with HepDirect nucleoside prodrugs for the treatment of HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...